HC Wainwright Reiterates Neutral Rating for Lyell Immunopharma (NASDAQ:LYEL)

Lyell Immunopharma (NASDAQ:LYEL)‘s stock had its “neutral” rating restated by investment analysts at HC Wainwright in a report released on Monday, Benzinga reports. They presently have a $1.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 5.47% from the company’s previous close.

Lyell Immunopharma Price Performance

Shares of NASDAQ LYEL opened at $0.95 on Monday. The stock has a market cap of $241.71 million, a PE ratio of -1.05 and a beta of -0.53. Lyell Immunopharma has a 1 year low of $0.86 and a 1 year high of $3.26. The firm has a fifty day moving average price of $1.28 and a 200-day moving average price of $1.78.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 33.35% and a negative net margin of 389,368.50%. On average, research analysts expect that Lyell Immunopharma will post -0.85 EPS for the current year.

Institutional Investors Weigh In On Lyell Immunopharma

A number of institutional investors have recently added to or reduced their stakes in LYEL. Dimensional Fund Advisors LP boosted its position in shares of Lyell Immunopharma by 197.8% during the second quarter. Dimensional Fund Advisors LP now owns 40,098 shares of the company’s stock worth $58,000 after acquiring an additional 26,635 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Lyell Immunopharma during the 1st quarter valued at about $64,000. China Universal Asset Management Co. Ltd. grew its position in shares of Lyell Immunopharma by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 49,238 shares of the company’s stock valued at $68,000 after purchasing an additional 19,287 shares in the last quarter. SG Americas Securities LLC increased its holdings in shares of Lyell Immunopharma by 78.1% in the third quarter. SG Americas Securities LLC now owns 57,566 shares of the company’s stock worth $79,000 after purchasing an additional 25,247 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of Lyell Immunopharma by 9.3% in the first quarter. ProShare Advisors LLC now owns 48,986 shares of the company’s stock worth $109,000 after buying an additional 4,170 shares in the last quarter. 66.05% of the stock is owned by hedge funds and other institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.